Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and its 45%-owned subsidiary, Sapu Nano (US) LLC, announced that the independent Safety Review Committee has completed its review of the initial three-patient safety cohort in the ongoing Phase 1b SP-03-B101 trial of Sapu003. The committee found no dose-limiting toxicities and recommended advancement to the next planned dose level. The company also announced plans to expand the study into Europe with additional clinical sites to broaden patient access and support enrollment.
This clinical milestone follows the publication of peer-reviewed research describing the scientific foundation of the Deciparticle nanomedicine platform and the intravenous everolimus formulation Sapu003. According to the company, the publication supports the platform’s scalable manufacturing capabilities, stability, and preclinical antitumor activity while reinforcing the ongoing clinical development program.
Sapu003 is part of Oncotelic’s pipeline of oncology and immunotherapy products. The company is a clinical-stage biopharmaceutical firm focused on addressing high-unmet-need cancers and rare pediatric indications. Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through joint ventures. Currently, the company owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership, which is advancing its own pipeline of drug candidates. Oncotelic also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through Oncotelic’s relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the platform and its ongoing joint development work with TechForce Robotics, the company’s strategic robotics and automation partner.
The positive safety review and planned European expansion signal progress in the clinical development of Sapu003. For leaders in business and technology, this development highlights the intersection of nanotechnology and AI in drug development. The Deciparticle platform’s scalable manufacturing and stability could reduce production costs and accelerate time-to-market for cancer therapies. The integration of PDAOAI and robotics further positions Oncotelic to leverage automation for efficient manufacturing, potentially setting a precedent for AI-driven biopharma operations.
Investors and industry observers should note that the advancement to the next dose level reduces early-stage risk, while European expansion may accelerate patient enrollment and data collection. This could strengthen Oncotelic’s position in the competitive oncology landscape, particularly for rare cancers where few treatment options exist.
For more information, visit www.oncotelic.com. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.
